Zestoretic 12.5 mg / 10 mg – DIN 02103729
Zestoretic is Hydrochlorothiazide and Lisinopril 12.5 mg / 10 mg (tablet), sold in Canada. It is used for high blood pressure and quitting smoking. It is supplied by Searchlight Pharma Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.
Sold in Canada
Hydrochlorothiazide and Lisinopril 12.5 mg / 10 mg
- Brand
- Zestoretic
- Strength
- Hydrochlorothiazide 12.5 mg / Lisinopril 10 mg
- Used for
- High blood pressure and quitting smoking
- Form
- Tablet
- Manufacturer
- Searchlight Pharma Inc
- Drug class
- ACE inhibitor (blood pressure and heart medicine)
- Sold in
- Canada
- DIN
- 02103729
Source: Health Canada's Drug Product Database. Last checked .
Report a mistake
What is Lisinopril and Hydrochlorothiazide used for?
Lisinopril and Hydrochlorothiazide is used for high blood pressure and quitting smoking.
- Medicine type
- ACE inhibitor (blood pressure and heart medicine); thiazide diuretic (water pill)
Official uses from the US prescribing label
Lisinopril and Hydrochlorothiazide Tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using Lisinopril and Hydrochlorothiazide Tablets, USP consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS ). In considering use of Lisinopril and Hydrochlorothiazide Tablets, USP it should be noted that Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-Blacks. (See WARNINGS, Head and Neck Angioedema ).
From the FDA-approved label on DailyMed (published Jul 24, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your medicine? Check the box
- The box or bottle shows DIN 02103729.
- It names Zestoretic, Hydrochlorothiazide and Lisinopril 12.5 mg / 10 mg.
- A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.
Sold in Canada as Zestoretic by Searchlight Pharma Inc.
In Canada: prescription only.
Ingredients
Active: Hydrochlorothiazide, Lisinopril
Other Lisinopril and Hydrochlorothiazide pills
- R706 Lisinopril and Hydrochlorothiazide White, round, 6 mm Used for high blood pressure and quitting smoking
- R707 Lisinopril and Hydrochlorothiazide Yellow, round, 8 mm Used for high blood pressure and quitting smoking
- R708 Lisinopril and Hydrochlorothiazide Pink, round, 8 mm Used for high blood pressure and quitting smoking
- LL B01 Lisinopril and Hydrochlorothiazide 12.5 mg / 10 mg Blue, hexagon, 7 mm Used for high blood pressure and quitting smoking
- H150 Lisinopril and Hydrochlorothiazide 12.5 mg / 10 mg White, round, 6 mm Used for high blood pressure and quitting smoking
- LL B02 Lisinopril and Hydrochlorothiazide 12.5 mg / 20 mg Yellow, round, 8 mm Used for high blood pressure and quitting smoking
- LL B03 Lisinopril and Hydrochlorothiazide 25 mg / 20 mg Orange, round, 8 mm Used for high blood pressure and quitting smoking
- N 20/25 Hydrochlorothiazide and Lisinopril Dihydrate 25 mg / 20 mg Orange, round Used for high blood pressure and quitting smoking